{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:18:10Z","timestamp":1786119490161,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,2]]},"abstract":"<jats:p>\n                    The clinical benefits of interleukin (IL)-17A therapies for psoriasis are well-substantiated. However, efficacy outcomes for moderate-to-severe plaque psoriasis (pPS) may vary across IL-17A treatments. Practitioners require evidence to guide treatment selection within the IL-17A class for biologic-na\u00efve patients with moderate-to-severe pPS. This study compares the effectiveness and safety of ixekizumab and secukinumab in such patients. A retrospective analysis of 5 years of electronic medical records (demographics, clinical characteristics, treatment outcomes, and adverse effects) was conducted on biologic-na\u00efve patients receiving IL-17A treatments for moderate-to-severe stable pPS. The study comprised 70 ixekizumab users (ET cohort) and 55 secukinumab users (SB cohort) from a single center. Concurrent therapies were evenly distributed across groups. Both cohorts exhibited significant reductions in percentage body surface area involvement and Psoriasis Area and Severity Index scores posttreatment (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001 for all). However, the SB cohort demonstrated greater reductions in percentage body surface area involvement (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001) and Psoriasis Area and Severity Index scores compared with the ET cohort. Physician Global Assessment of treatment response favored the SB cohort (1.1 [1.4\u20131] vs 1.1 [1.5\u20131]). Systemic organ infections were more prevalent in the SB cohort (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.009). Following treatment, 26 (37%) and 24 (44%) patients in the ET and SB cohorts, respectively, achieved mild disease activity (\u22641 on Physician Global Assessment). The SB cohort experienced a higher incidence of adverse effects (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001, risk ratio\u2005=\u20050.52; 95% confidence interval\u2005=\u20050.37\u20130.73,\n                    <jats:italic toggle=\"yes\">I<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    \u2005=\u20050%). In Chinese biologic-na\u00efve patients with moderate-to-severe pPS, secukinumab may be associated with a superior response but a higher incidence of adverse effects compared with ixekizumab.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000046843","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T15:03:06Z","timestamp":1767711786000},"page":"e46843","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Secukinumab compared to ixekizumab in biologic-na\u00efve Chinese individuals afflicted with moderate-to-severe plaque psoriasis: A retrospective single-center analysis"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5388-8944","authenticated-orcid":false,"given":"Dayu","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Dermatology Venereal disease, Beijing Shijitan Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260218","doi-asserted-by":"crossref","first-page":"e31527","DOI":"10.1097\/MD.0000000000031527","article-title":"Effects of methotrexate and etanercept treatment in moderate and severe psoriasis.","volume":"101","author":"Benites","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"R2-20260218","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/jdv.16124","article-title":"Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease.","volume":"34","author":"Reich","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R3-20260218","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09546634.2024.2371045","article-title":"Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials.","volume":"35","author":"Korman","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"R4-20260218","doi-asserted-by":"crossref","first-page":"5464","DOI":"10.1007\/s12325-023-02672-1","article-title":"Safety and efficacy of ixekizumab in Chinese adults with moderate-to-severe plaque psoriasis: a prospective, multicenter, observational study.","volume":"40","author":"Ying","year":"2023","journal-title":"Adv Ther"},{"key":"R5-20260218","doi-asserted-by":"crossref","first-page":"46381","DOI":"10.18632\/oncotarget.18453","article-title":"Clinic characteristics of psoriasis in China: a nationwide survey in over 12000 patients.","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"R6-20260218","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis.","volume":"2","author":"Greb","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"R7-20260218","first-page":"1","article-title":"Real-world biologic and apremilast treatment patterns in patients with psoriasis and psoriatic arthritis.","volume":"27","author":"Feldman","year":"2021","journal-title":"Dermatol Online J"},{"key":"R8-20260218","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40265-020-01261-8","article-title":"JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors.","volume":"80","author":"Nogueira","year":"2020","journal-title":"Drugs"},{"key":"R9-20260218","doi-asserted-by":"crossref","first-page":"871e1","DOI":"10.1016\/j.jaad.2013.12.018","article-title":"Patient perspectives in the management of psoriasis: results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey.","volume":"70","author":"Lebwohl","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"R10-20260218","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09546634.2024.2358150","article-title":"Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: a real-life retrospective study (VESPA-Study).","volume":"35","author":"Orsini","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"R11-20260218","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2023.1341708","article-title":"Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis).","volume":"14","author":"Gargiulo","year":"2024","journal-title":"Front Immunol"},{"key":"R12-20260218","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis.","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"R13-20260218","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/bjd.12025","article-title":"Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.","volume":"167","author":"Spuls","year":"2012","journal-title":"Br J Dermatol"},{"key":"R14-20260218","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s12325-022-02379-9","article-title":"Comparative effectiveness of biologics across subgroups of patients with moderate-to-severe plaque psoriasis: results at week 12 from the PSoHO study in a real-world setting.","volume":"40","author":"Lynde","year":"2023","journal-title":"Adv Ther"},{"key":"R15-20260218","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1111\/jdv.16180","article-title":"Real-world evidence of secukinumab in psoriasis treatment - a meta-analysis of 43 studies.","volume":"34","author":"Augustin","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R16-20260218","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","article-title":"Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.","volume":"366","author":"Leonardi","year":"2012","journal-title":"N Engl J Med"},{"key":"R17-20260218","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaad.2019.11.015","article-title":"Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab.","volume":"82","author":"Blauvelt","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R18-20260218","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1007\/s13555-021-00627-4","article-title":"Comparison of real-world treatment patterns among biologic-experienced patients with psoriasis treated with Ixekizumab or Secukinumab over 18 months.","volume":"11","author":"Blauvelt","year":"2021","journal-title":"Dermatol Ther"},{"key":"R19-20260218","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s13555-024-01182-4","article-title":"Long-term effectiveness and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: a five-year multicenter retrospective study-IL PSO (Italian Landscape Psoriasis).","volume":"14","author":"Valenti","year":"2024","journal-title":"Dermatol Ther"},{"key":"R20-20260218","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40264-024-01427-3","article-title":"The safety of ixekizumab in chinese adults with moderate-to-severe plaque psoriasis: analyses from a prospective, single-arm, multicenter, 12-week observational study.","volume":"47","author":"Li","year":"2024","journal-title":"Drug Saf"},{"key":"R21-20260218","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jaad.2019.02.031","article-title":"Secukinumab drug survival in patients with psoriasis: a multicenter, real-world, retrospective study.","volume":"81","author":"Torres","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R22-20260218","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/20406223241230180","article-title":"Real-world safety and effectiveness of secukinumab in adult patients with moderate to severe plaque psoriasis: results from postmarketing surveillance in Korea.","volume":"15","author":"Kim","year":"2024","journal-title":"Ther Adv Chronic Dis"},{"key":"R23-20260218","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jaad.2017.05.033","article-title":"The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study.","volume":"77","author":"Bagel","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R24-20260218","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/jdv.12861","article-title":"Comparison of three methods for measuring psoriasis severity in clinical studies (Part 2 of 2): use of quality of life to assess construct validity of the lattice system physician\u2019s global assessment, psoriasis area and severity index and static physician\u2019s global assessment.","volume":"29","author":"Simpson","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R25-20260218","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3390\/jpm14121169","article-title":"Efficacy and safety of intra-class switching from ixekizumab to secukinumab in patients with plaque psoriasis: a multicenter retrospective study.","volume":"14","author":"Bernardini","year":"2024","journal-title":"J Pers Med"},{"key":"R26-20260218","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s13555-024-01134-y","article-title":"Effectiveness of ixekizumab in Chinese patients with moderate-severe plaque psoriasis with special area involvement: subanalysis of a prospective, multicenter, observational real-world study.","volume":"14","author":"Li","year":"2024","journal-title":"Dermatol Ther"},{"key":"R27-20260218","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s13555-023-01086-9","article-title":"Comparative effectiveness and durability of biologics in clinical practice: month 12 outcomes from the international, observational psoriasis study of health outcomes (PSoHO).","volume":"14","author":"Pinter","year":"2024","journal-title":"Dermatol Ther"},{"key":"R28-20260218","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s13555-021-00511-1","article-title":"Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis.","volume":"11","author":"Armstrong","year":"2021","journal-title":"Dermatol Ther"},{"key":"R29-20260218","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12895-019-0088-2","article-title":"A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies.","volume":"19","author":"Callis Duffin","year":"2019","journal-title":"BMC Dermatol"},{"key":"R30-20260218","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.oooo.2022.05.002","article-title":"Diagnostic efficacy of physical examination, preoperative ultrasound, and\/or computed tomography in detecting lymph node metastasis: a single-center retrospective analysis of patients with squamous cell carcinoma of the head and neck.","volume":"134","author":"Zhang","year":"2022","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"R31-20260218","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s13555-020-00373-z","article-title":"Treatment of psoriasis with secukinumab in challenging patient scenarios: a review of the available evidence.","volume":"10","author":"Wu","year":"2020","journal-title":"Dermatol Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046843","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:25:03Z","timestamp":1786040703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046843","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"assertion":[{"value":"2025-08-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}